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We report the impact of anti-urothelial autoantibody (AUAb) on urinary bladder phenotype in BALB/c
micedeficientoftheFccRIIbandPD-1.AUAbwaspresentinserumsamplesfromapproximatelyhalfofthe
double-knockout (DKO) mice, as detected by immunofluorescence and immunoblots for urothelial
proteinsincludinguroplakinIIIa.TheAUAb-positiveDKOmiceshoweddegenerationofurothelial plaque
and umbrella cells, along with infiltration of inflammatory cells in the suburothelial layer. TNFa and IL-1b
were upregulated in the bladder and the urine of AUAb-positive DKO mice. Voiding behavior of mice was
analyzed by the Voided Stain on Paper method. 10-week-old and older AUAb-positive DKO mice voided
significantly less urine per void than did wild type (WT) mice. Furthermore, administration of the
AUAb-containing serum to WT mice significantly reduced their urine volume per void. In summary, this
report presents a novel comprehensive mouse model of autoimmune cystitis.
A
n autoimmune mechanism has been postulated as a candidate cause for non-bacterial inflammatory
diseases of the bladder such as interstitial cystitis, eosinophilic cystitis and lupus cystitis in human
1–3.
However, direct mechanistic association between autoimmune processes and functional changes in the
bladder has not been established clinically. In experimental model, administration of exogenous molecule has
been shown to elicit inflammatory change in the bladder
4. Further, recent studies described the mechanism of
autoimmune responses in the bladder by analyzing transgenic mice that constitutively express a self-antigen in
the bladder epithelium, but did not elucidate whether the autoantibody could bepathogenic for bladder function
in behavioral level or not
5,6. In short, role of autoimmune processes in bladder pathophysiology is yet incom-
pletely elucidated.
During the storage of urine in the bladder, umbrella cells, which are located on the surface of the bladder
epithelium (urothelium), play an important role in the bladder barrier function
7. Uroplakin (UPK) Ia, Ib, II, and
IIIa are components of urothelial cell plaques, whose function is to reduce the transcellular passage of water
through the urothelium
8. Mice defective of UPKs show elevated water permeability in the urothelium
9, vesicour-
eteral reflux, hydronephrosis
10 and decreased bladder capacity
11, demonstrating the importance of these barrier
moleculesinnormalbladderfunction.RecentstudyshowedthatimmunizationwithrecombinantmouseUPKII
might cause bladder specific inflammation and urinary frequency, though this study failed to describe any
histological changes in urothelium, which includes UPK II proteins
12.
The BALB/c mouse deficient in low affinity type IIb Fc receptor for IgG (FccRIIB or Fcgr2b)a n d
programmed cell death 1 (PD-1 or Pdcd-1) (BALB/c-Fcgr2b
2/2Pdcd1
2/2 mouse / the DKO mouse) exhibits
autoimmune phenotypes including autoimmune dilated cardiomyopathy
13 and gastritis
14. Interestingly,
serum samples derived from the DKO mice also react to the urothelium and to UPKIIIa, and hydronephrosis
is reported as a phenotypic consequence of anti-urothelial autoantibody (AUAb) due to periureteral inflam-
mation
14. As an extension of this study, we hypothesized that ablation of urothelium by the autoantibody
should also impair bladder function. Therefore we analyzed the bladder of DKO mice to examine impact of
the anti-urothelial antibody (AUAb), using biological and physiological techniques including a method
reported as ‘‘Voided Stain on Paper (VSOP) method’’
15, and demonstrate here a novel comprehensive mouse
model of autoimmune cystitis.
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ExpressionofAUAbinDKOmice.The presence of AUAb in serum
samples was detected using mouse serum as primary antibodies
for immunofluorescence (IF) of WT mouse bladder (Supplementary
Fig. 1A) and immunoblotting for UPKIIIa, a component of urothe-
lial plaque (Supplementary Fig. 1B)
14.A U A bi ns e r u mo ft h eD K O
mice could be detected as early as 7 weeks of age by the IF. At 10-
week-old, approximately half of DKO mice (7/13; 53.8%) expressed
AUAb (Supplementary Fig. 1A right), but no WT mice did (0/10; 0%,
Supplementary Fig. 1A left). In addition, the DKO mouse serum with
positive immunoreactivity for the urothelium by IF, also recognized
uroplakin 3A (UPKIIIa) by immunoblotting, indicating that UPKIIIa
is one of the target proteins of AUAb (Supplementary Fig. 1B).
These AUAb-positive DKO mice remained positive until 16-
week-old,whilenonewAUAb-positivemiceappearedafter10-week.
The positive rate of AUAb in the serum samples from DKO mice
varied by the colony as shown in the former and current studies
(35.3% and 53.8%, respectively)
14.
DKO mice expressing AUAb have degenerated urothelium. We
then evaluated the impact of AUAb on bladder morphology, by com-
paring wild-type mice, DKO mice with AUAb (AUAb-positive DKO
mice), and those without AUAb (AUAb-negative DKO mice). There
was marked disarrangement of urothelial plaque on the surface of the
bladder of AUAb-positive DKO mice, but not in WT or AUAb-
negative DKO mice (Fig. 1A–I). Hematoxylin and eosin (H&E)
staining, and more prominently scanning electron microscopy (SEM),
showed a disarranged cellular structure of the bladder epithelium in
AUAb-positive DKO mice at 16-week-old compared to WT mice or
AUAb-negative DKO mice (Fig. 1A, B and D, E). The surface ofbladder
epithelium from AUAb-positive DKO mice exhibited poorer plaque
formation, exposing bare surface of smaller epithelial cells beneath it
(Fig. 1E). This morphological difference correlated with weaker staining
of UPKIIIa in the bladders of AUAb-positive DKO mice compared to
bladders from WT or AUAb-negative DKO mice (Fig. 1G, H, and I).
These morphological features showed a close similarity to that of
UPKIII KO mice reported by Hu et al.
10, suggesting that AUAb may
cause immunological ablation of UPKIII and apical cell layer of the
urothelium.
Infiltration of inflammatory cells at the suburothelial layer of
AUAb-positive DKO mice. The other remarkable morphological
feature in the AUAb-positive DKO mice was massive infiltration
of inflammatory cells in the suburothelial layer, which was never
observed in WT or AUAb-negative DKO mice (Fig. 2A–C). There
wasmarked infiltration of c-kit-positive inflammartory cells into the
suburothelial layer of AUAb-positive DKO mice (Fig. 2D-F). The c-
kit-positive cell count was significantly elevated in AUAb-positive
DKO mice compared with AUAb-negative DKO or WT mice
(Fig. 2G). Although c-kit has been known as a marker for mast
cells
16, these c-kit-positive cells did not have typical morphological
feature of mast cells. There were also inflammatory cells positively
stained for CD4 (T cell marker), CD11c (dendritic cell marker) and
B220 (activated B cell marker) (Fig. 2I, K, M), while immu-
noreactivity for F4/80, which is the marker of macrophage was not
elevated (Fig. 2O).
Expression of inflammatory cytokines in the suburothelial layer.
In addition to morphological analyses, we analyzed the inflam-
matory process by identifying inflammatory factors using PCR
analyses. TaqMan low-density array (TLDA) showed that mRNA
expression levels of six molecules (Il2ra, Tnf, Icos, Il1b, Socs1,
Vcam1) were significantly upregulated in the bladder of AUAb-
positive DKO mice, as compared to WT mice (Supplementary Fig.
2A:p,0.01).Meanwhile,ELISAassayforurinarycytokinesrevealed
that the protein level of seven molecules (GM-CSF, TNFa, IL-1a,G -
CSF, IL-1b, RANTES, MIP-1b) was significantly upregulated in the
urine of AUAb-positive DKO mice, as compared to WT mice
(Supplementary Fig. 2B: p,0.05). Consequently, two molecules,
TNFa and IL-1b were elevated in both bladder mRNA and urine
proteinlevels(Fig.3A).Ofthese,TNFaisknownasamajormediator
Figure 1 | DKOmiceexpressingAUAbhavedegeneratedurothelium. HistologicalanalysesofbladdertissueofWT(A,D,G),AUAb-positive DKO(B,
E, H), and AUAb-negative DKO (C, F, I) mice are displayed. (A–C) Hematoxylin and eosin (H&E) stain showed smaller epithelial cells including
umbrella cells in the bladder of AUAb-positive DKO mice (B) than WT (A) and AUAb-negative DKO mice (C). (D–F) Scanning electron microscopy
(SEM) revealed epithelial plaque in the bladder of WT (D) and AUAb-negative DKO mice (F); however, the size of plaques was decreased in AUAb-
positiveDKOmice(E).(G–I)TheintensityofstainingforUPKIIIawasreducedintheurotheliallayerofAUAb-positiveDKOmice(H)comparedtoWT
(G) and AUAb-negative DKO mice (I). Bars indicate 30 mm in A–C, G–I, 10 mm in D–F.
www.nature.com/scientificreports
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diseases such as rheumatoid arthritis or inflammatory bowel
disease
17,18, and is also reported to play a crucial role in the
pathology of inflammatory diseases of the bladder in animal
models of neurogenic cystitis
19,20. In the AUAb-positive DKO mice,
the tnf mRNA expression level was upregulated in the stomach and
the bladder, suggesting that the inflammatory process is not
systemic, but involved limited number of organs, against which
specific antibody is expressed, the stomach
14 and the bladder
(Fig. 3B).
Another separate ELISA study replicated the finding that urine of
AUAb-positive DKO mice contained a significantly higher level of
TNFa compared to WT mice (Fig. 3C: p,0.05). This elevated urine
TNFa (Fig. 3C) may not derive from the kidney, but should account
for overexpression of this molecule in the diseased bladder, since it
was neither elevated in the kidney nor in the serum, (Fig. 3B).
In summary, the elevation of the inflammatory mediators includ-
ing TNFa indicated the significance of inflammation process in the
bladderofAUAb-positiveDKOmice,whichmadeustofocusonthe
phenotype in context of the bladder function.
Presence of AUAb in the serum is associated with impaired
bladder storage function. To evaluate the behavioral consequence
of the inflammation in AUAb-positive mice, we analyzed urination
ofthemicebyamethodreportedas‘VSOPmethod’byus
15.From10
to 16- week-old, the AUAb-positive DKO mice (n57) voided
significantly less urine per void than did WT mice (n510,
p,0.01), while there were no significant differences between
AUAb-negative DKO (n56) and the WT mice (Fig. 4A upper).
Because AUAb-positive DKO mice had lower body weight than
WT mice, we also examined the data with correction by body
weight, and confirmed that the urine volume per void of AUAb-
positive DKO mice was still significantly smaller than that of WT
mice (Fig. 4A middle). The significant difference was also noted
when the urine volume per void was adjusted as the ratio against
the urine volume per void in 4-week-old (urine volume per void
index, Fig 4A lower). Urine volume per void of AUAb-negative
DKO mice showed slight and transient decrease compared to WT,
but did not reach statistical significance except on the weight-
adjusted data at 10-week-old (Fig. 4A middle), suggesting that
presence of AUAb had greater impact on the bladder function
than the genetic modification itself.
Based on these findings, we examined whether AUAb-containing
serum is a pathogenic factor by itself in animals without genetic
alteration. Intraperitoneal administration of the AUAb-containing
serum resulted in a significant reduction in urine volume per void as
comparedtotheWTserum-treatedmice(shownasurinevolumeper
voidindex, Fig.4B),butno reductioninbodyweight,demonstrating
that AUAb inhibits the growth of the bladder capacity. The bladder
from mice 1 week after last of 4 injections of AUAb-positive sera
Figure 2 | C-Kit expressing cells are significantly elevated in the suburothelial layer of AUAb-positive DKO mice. (A–F) H&E staining (A–C) and
immunohistochemistryforc-Kit(D–F)areshown.ThereweremanyinflammatorycellsbeneaththeurotheliumofAUAb-positiveDKOmiceandc-Kit-
positivecellswereobservedinthelesion(B,E),thoughtherewerenoinfiltration ofinflammatorycellsnorc-Kit-positivecellsinthespecimenofWT(A,
D)andAUAb-negativeDKO(C,F)mice.(G)Therewasasignificantincreaseinthenumberofc-Kit-positivecellsinthebladderofAUAb-positiveDKO
mice (&:n 55) compared to WT (.:n 55) and AUAb-negative DKO mice (m:n 55) under microscopic observation (**p,0.01).
(H–O) Immunohistochemistry for the other important inflammatory cells is shown for bladder of WT (H, J, L, N) and AUAb-positive DKO mice (I, K,
M,O). CD4 (T-cell marker: H, I), CD11c (dendritic cell marker: J, K) and B220 (activated B-cell marker: L, M) were prominent in the bladder ofAUAb-
positive DKO mice (I, K, M) compared to the WT bladder that had no infiltration of inflammatory cells (H, J, L) (positive cells are indicated by white
arrows),whiletherewerenoremarkablestainingofF4/80(macrophagemarker:N,O)inAUAb-positiveDKObladder(O)andtherewerenoinfiltration
of inflammatory cells in WT bladder (N). Bars indicate 100 mm in A–C, 30 mm in D–F, H–O.
www.nature.com/scientificreports
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which was not observed in mice after injection of control serum
(Fig. 4C upper left). The intensity of staining for UPKIIIa was
reduced in the urothelial layer of the bladder of mice after injection
of AUAb-containing serum (Fig. 4C lower left) compared to the
bladderofmiceafterinjectionofcontrolserum(Fig.4Clowerright).
Discussion
The present study demonstrates that BALB/c-Fcgr2b
2/2Pdcd1
2/2
mouse (the DKO mouse) expressing AUAb is a novel animal model
for autoimmune cystitis. AUAb-positive DKO mouse is a novel dis-
ease phenotype exhibiting three distinct features: disarrangement of
urotheliallayer, inflammation inthe suburothelial layerand reduced
functional bladder capacity.
The association of AUAb and these three findings could be
explained by various possible mechanisms. First intriguing association
is found between disarranged urothelial layer and inflammation in the
suburothelial layer. Infiltration of the inflammatory cells could be
explained either as inflammation directly following antibody-antigen
reaction in the urothelial layer, or as consequence after disruption of
impermeable barrier function by the urothelium against ions, water
and urea
21, which entails infiltration of urine into interstitium of the
bladder. The target of AUAb, uroplakin is known as a critical factor
for urothelial barrier function
7–9. Upk3a knockout mice have a degen-
erated leaky urothelium
9, and Upk2 knockout mice show a frequent
urination pattern with reduced urine volume per void
11. Since AUAb-
positive DKO mice show similar phenotypic changes such as degen-
erated urothelium and reduced urine volume per void in this study
(Fig. 1 and Fig. 4A, B and C), alterations in the morphological and
functional properties of AUAb-positive DKO mice could be attrib-
utable to degenerated, leaky bladder urothelium associated with
AUAb.
The other interesting phenotype is reduction in functional blad-
der capacity of AUAb-positive DKO mice. Although these mice
are genetically modified, the reduction of the capacity does not
seem to be congenital, but most likely attributable to appearance
Figure 3 | HigherlevelofTNFaisdetectedinthebladderandtheurineofAUAb-positiveDKOmice. (A)TLDAindicatedthatmRNAexpressionlevel
of six inflammatory molecules was significantly upregulated in the bladder of AUAb-positive mice compared to WT mice ({{ p,0.01). Urine protein
assay also revealed that seven inflammatory proteins were significantly upregulated in the urine of AUAb-positive DKO mice compared to WT mice
({ p,0.05). IL-1b and TNFa were expressed higher in both. (B) TNFa mRNA was elevated in the stomach and bladder of AUAb-positive DKO mice
(*p,0.05). (C) ELISA assay for mouse TNFa has revealed that AUAb-positive DKO mice urine samples contain significantly higher level of TNFa than
WT mice (*p,0.05).
www.nature.com/scientificreports
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associated with it for three reasons. First, the capacity of the mice
is similar until 4 week, after which AUAb appears. Second, there
are distinct difference between AUAb-positive and -negative DKO
mice. Last, the AUAb-positive serum alone could induce similar
functional impairment in WT mice. The possibility of neurogenic
bladder dysfunction caused by inflammation in the spinal cord
seemed negative based on results of the histological analysis of
spinal cord sections (data not shown), and the inflammatory pro-
cess producing various cytokines including TNFa in the bladder
itself seems to impair bladder function. In this process although its
functional role is not determined, TNFa level seems to reflect the
localized inflammatory process. It is likely that AUAb causes this
process by antigen-antibody reaction, although precise following
mechanism is unclear. It is rather unlikely that antibody-depend-
ent cellular cytotoxicity could be the cause for the urothelial
destruction, since histologically there is no infiltration of inflam-
matory cells into urothelium in spite of massive inflammation of
the bladder, while the activation of complement pathway may be a
subject for future study. However, as a limitation of our study, we
cannot conclude that AUAb is the only causative factor for the
bladder inflammation, as there may be additional factor in sera of
AUAb-positive DKO mice causing cystits, and we could not purify
the immunoblobulin for sera transfer experiments for technical
reason, although important cytokine such as TNFa was undetect-
able in the serum of AUAb-positive mice.
Figure 4 | AUAb-containing serum is pathogenic to bladder storage function. (A) Urine volume per void of female AUAb-positive DKO mice
(.:n 57),femaleAUAb-negativeDKO mice(m:n 56),andfemaleWTmice(&:WT ,n 510) wasrecordedfrom4-week-oldto16-week-oldbytheVSOP
method. From 10 to 16-week-old, there were significant differences (**p,0.01) in urine volume per void between AUAb-positive DKO mice and WT
mice,althoughtherewerenosignificantdifferences between AUAb-negativeDKO miceand WTmice (upperpanel). Thedataadjustedbybodyweightare
shown in the middle panel and the data shown as urine volume per void index (adjusted at 4-week’s urine volume per void) are in the lower panel. There
were also significant differences between AUAb-positive DKO (.) and WT (&) from 10 to 16-week-old (*p,0.05), although there were no significant
differences between AUAb-negative DKO (m) and WT (&) except the urine volume adjusted by body weight at 10-week-old (#p,0.05). (B) Serum
samples from AUAb-positive DKO mice (.,n 55) and serum samples from WT mice (&,n 55) were injected into WT female mice intraperitoneally
(300 ml/bodyat4-, 7-, 10-week-old;arrow).The urinevolumeper voidrecordedbyVSOPmethodrevealed asignificant decreaseofurine volumepervoid
by administration of the serum from AUAb-positive DKO mice, compared with the serum from WT mice (shown as urine volume per void index). Data
are expressed as means 6 SE for each group. (C) H&E staining of the mouse bladder after injection of AUAb-containing serum (upper right) showed the
disarrangement of urothelial plaque, which was not observed in the bladder after injection of control serum (upper left). The intensity of staining for
UPKIIIa was reduced in the urothelial layer of the bladder of AUAb-containing serum injected mice (lower left) compared to the bladder of control serum
injected mice (lower right). Bars indicate 100 mm.
www.nature.com/scientificreports
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the bladder itself, since the net wet weight of the retrieved bladders
was not different between each group (data not shown). The other
more likely possibility is that the inflammation makes animals feel
urinary fullness or pain more keenly and frequently, as seen in the
clinical patients with bladder inflammation, although there was no
sign of bladder pain such as lower abdominal licking or freezing on
the AUAb-positive DKO mice.
By any mechanism, the AUAb was shown to play a key role in
inducing the bladder dysfunction seen in DKO mice, but trans-
lational potential of this model to human pathology is still elusive.
Therearefeaturesinthismodelresemblingpathologicalprocessesof
human disease like interstitial cystitis or lupus cystitis. For example,
AUAb-positive DKO mice had increased number of c-kit positive
cells and activated B cells in the bladder. C-kit has been known as a
marker for mast cells
16, and degranulation of mast cells results in
release of chemical mediators such as histamine or nerve growth
factor, reportedly linked to neural changes in humans with intersti-
tial cystitis
20. However, we could not conclude morphologically that
thec-kitpositivecellsintheAUAb-positive DKOmice aredefinitely
mast cells, and yet little is known about the precise functional role of
c-kit-positive cells in bladder diseases. Though there is also a report
aboutactivatedBcellsinthebladdersubmucosallesionofinterstitial
cystitis patients
22, the pathological features of the animal is radically
different from clinical interstitial cystitis in human. Beside this, the
most different point from the human pathology is the presence of
autoantibodies against urothelium, which have not been reported in
humanpatients.Atthesametime,itisalsounlikelythatAUAbexists
in human at the detrimental level as seen in the DKO, since develop-
ment of hydronephrosis itself is rarely seen in non-bacterial inflam-
matory diseases of the urinary tract. We can predict from our
findingsthat,ifAUAbexistsinthehumanbladderdiseases,itshould
appear either in a extremely limited number of severest cases, or just
transiently at a lower level than seen in DKO mice.
Experimentally, the pathophysiology of AUAb-positive DKO
mice presents a novel animal model of bladder pathology: bladder
inflammation associated with autoantibody and behavioral pheno-
type. Our system is distinct from reported autoimmune cystitis
models in several aspects
4–6,12. The reported models failed to show
either change in behavioral phenotype
5,6 , histological changes in the
urothelium
12, or a characterized pathogenic factor as AUAb
4, all of
which are seen in our AUAb-positive DKO mice. Moreover, the
appearance of AUAb does not require stimulation of exogenous
material such as ovalbumin for sensitization, showing that defective
tolerance mechanism itself is enough to induce spontaneous sens-
itization against urothelium, generating potent autoantibody to alter
the micturiton behavior. In summary, the AUAb-positive DKO
mouse demonstrates that autoimmunity can induce significant
impairment of the bladder function.
In conclusion, this report characterizes a novel comprehensive
mouse model of autoantibody-associated cystitis, which provides
various insights about establishment of the bladder autoimmunity.
Methods
Animals. Wild-type BALB/c mice were purchased from Clea Japan, Inc. (Tokyo,
Japan).BALB/c-Pdcd1
2/2andBALB/c-Fcgr2b
2/2micewerekindlyprovidedbyDrs.
Tasuku Honjo (Kyoto University), Jeffrey V. Ravetch (Rockefeller University), and
Toshiyuki Takai (Tohoku University)
13,23. BALB/c- Fcgr2b
2/2 Pdcd1
2/2 mice were
produced as we described previously
14. The Institute of Laboratory Animals at the
Kyoto University Graduate School of Medicine approved all mouse protocols. All
animals were maintained under specific pathogen-free conditions.
Immunofluorescence (IF). The existence of AUAb in the serum of mice was
examined by utilizing it as a primary antibody of IF for mouse bladder section. The
bladder tissues were collected from wild-type BALB/c mice, which were snap frozen
in the OCT compound. Cryosections were fixed with CytoFix (BD Biosciences, CA,
USA) and incubated with x100 diluted serum from mice, followed by FITC labeled
anti–mouse IgG Ab (Jackson ImmunoResearch Laboratories, Inc., PA, USA).
Sections were examined with an Eclipse E1000M microscope (Nikon, Tokyo, Japan).
Immunoblotting. Mouse UPKIIIa partial cDNA (corresponding to W19 to A125)
was subcloned into pGEX-6P-1 vector (GE Healthecare, Buckinghamshire, UK) and
GST-fusion protein of mouse UPKIIIa (GST-UPKIIIa) was expressed and purified
according to the manufacturer’s instruction
14. The purified solution (20 mg) was
boiled for 5 min in a SDS sample buffer solution and separated by SDS-PAGE on a
10% Tris-HCl mini gel and transferred onto a polyvinylidene difluoride membrane
following standard methods. Membranes were incubated with x100 diluted mouse
serum or mouse monoclonal antibody (mAb) against UPKIIIa (PROGEN,
Heidelberg, Germany) for two hours at room temperature and visualized by F(ab2)’
fragment of goat anti-mouse IgG (Jackson Immuno Research, PA, USA) with
enhanced chemiluminescent detection system (GE Healthcare, Buckinghamshire,
UK).
Immunohistochemistry (IHC) and scanning electron microscopy. Bladder tissues
were collected after emptying the bladder of mice by pressing their lower abdomen.
Thefollowingantibodieswereused:anti-UPKIIIa(PROGEN,Heidelberg,Germany),
anti-c-kit (Novocastra, Newcastle, UK), anti-TNFa (Santa Cruz, CA, USA), anti-
CD11c and anti-F4/80 (Abcam, MA, USA), anti-CD4 (BD Pharmingen, CA, USA),
anti-B220 (eBioscience, CA, USA). Tyramide signal amplification-avidin-biotin
complex (TSA-ABC) method was used for IHC
24. Sections were examined with an
Eclipse E1000M microscope (Nikon, Tokyo, Japan). For scanning electron
microscopy, bladders were fixed with 2% glutaraldehyde in 0.1 M phosphate buffer
(pH7.2),postfixedwith1%OsO4and0.1 Msucrosein0.1 Mphosphatebuffer
25and
examined by using an electron microscope (Hitachi H7000, Tokyo, Japan).
RNA isolation and quantitative RT-PCR. RNA was isolated from mouse organs
using the RNeasy mini kit (Qiagen, CA, USA). Whole bladders were used. RNA
(1 mg)wasreverse-transcribedusingtheFirst-StrandcDNAsynthesiskit(Amersham
Pharmacia Biotech, NJ, USA), following manufacturer’s protocol. Quantitative real-
time PCR with SYBR Green PCR Master Mix (Applied Biosystems, CA, USA) was
doneusingtheGeneAmp5700SequenceDetectionSystem(AppliedBiosystems,CA,
USA) with the relative standard curve method, at 95uC for 15 seconds and 60uC for 1
minute. PCR efficiency was examined byserially diluting the template cDNAand the
meltingcurvedatawerecollectedtocheckthePCRspecificity
26.NoPCRproductwas
detected in control samples in which reverse transcriptase was omitted. An internal
loadingcontrolofglyceraldehyde-3-phosphatedehydrogenase(GAPDH)expression
was used for all genes of interest. Results were quantified using the relative standard
curve method. The primers used were as follows: GAPDH (452 bp) sense,
59-ACCACAGTCCATGCCATCAC-39, and antisense,
59-TCCACCACCCTGTTGCTGTA-39; TNFa (60 bp) sense,
59-CCCTCACACTCAGATCATCTTCT -39, and antisense
59-GCTACGACGTGGGCTACAG -39. Each PCR regimen involved 5 minutes of
initial denaturation step at 95uC followed by 38 cycles at 94uC for 60 seconds, 60uC
(TNFa)o r6 5 uC (GAPDH) for 60 seconds, and 72uC for 1 minute and 30 seconds.
TaqMan low-density array (TLDA). Gene expression analysis was performed using
TaqMan immune-profiling/inflammation low-density arrays (Applied Biosystems,
CA, USA), according to manufacturer’s protocol. Real time RT-PCR amplification
was performed on an ABI Prism 7900 H.T. Sequence Detection system (Applied
Biosystems, CA, USA). Thermal cycling conditions were as follows: 2 minutes at
50uC, 10 minutes at 94.5uC, and for 40 cycles, 30 seconds at 97uC and 1 minute at
59.7uC. TLDA cards were analyzed with relative quantification (RQ) documents and
RQ manager software for automated data analysis (Applied Biosystems, CA, USA).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was selected as the internal
control.
Urine cytokine assay. Inflammatory cytokine concentrations in urine samples from
AUAb-positive DKO and WT mice were analyzed by Bio-Plex Mouse Cytokine
Group I 23-Plex (Bio-Rad, PA, USA) according to the manufacturer’s instruction.
TNFa ELISA assay. TNFa concentration in mice urine samples were analyzed by
another ELISA assay, Mouse TNFa ELISA (eBioscience, CA, USA), according to the
manufacturer’s instruction.
Voided Stain on Paper (VSOP) method. Voiding behavior of mice was analyzed as
described previously
15. Briefly, the mice were fed with 50 ml/g of distilled water via
gastric tube and placed on a screen above the filter paper, and their urination was
recorded over two hours. The recorded stain areas were copied to another paper and
calculated to the volume by computer software Photoshop (Adobe, USA). Age-
dependent changes in bladder volume were also evaluated, either as net volume,
volume adjusted to body weight, or using the urine volume per void index calculated
astheratioofurinevolumepervoidof4,7,10,13or16-week-oldmiceagainstthatof
4-week-old mice.
PathogenicitytestoftheAUAb-containingserum.Testserumsampleswerepooled
from20DKOmiceat16to20-week-old,andconfirmedtohaveAUAbbyIF.Control
serum samples were pooled from 15 age-matched BALB/c wild-type mice. These
serum samples were preserved at 280uC. The pooled serum (300 ml/body) was then
injected intraperitoneally to WT female mice at 4, 7 and 10-week-old (n55 for each
group).UrinevolumepervoidwasassessebyVSOPmethodat4,7,10,and13-week-
old. On the other session, the serum was injected on the WT mice at 4, 7, 10, and
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Statistical analysis. Results are expressed as means 6 SE. Statistical comparisons
between two experimental groups were performed by Student’s paired and unpaired
t-test using Statview 5.0 (SAS institute, Inc., NC, USA), and P value ,0.05 was
considered as significant.
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